Motus GI Holdings Inc. (MOTS) stock prices were up by 18.17% as of the end of the trading day on October 26th 2021. This brought the price per share up to USD$0.72. Subsequent premarket fluctuations saw the stock dip by 6.44%, bringing it down to USD$0.67.
Pure-Vu System Results
October 26th 2021 saw MOTS stock announce the results from its independent single center study of the Pure-Vu System. The Pure-Vu System is an adjunct to colon cleansing in patients suffering from inadequate bowel preparation (IBP). These results were featured in a poster presentation at the 2021 American College of Gastroenterology (ACG) Annual Scientific Meeting. The company is bolstered by the positive results of its real-world, independent study of the Pure-Vu System. This supports both inpatient and outpatient procedures for screening and emergency colonoscopies at the ACG meeting.
Details of MOTS Stock’s Study
MOTS stock has carried out extensive research of the Pure-Vu System around inpatient screening colonoscopies following bowel preparation. Following this research, the evaluation of the Pure-Vu System comprised three patient cases where it was successfully used in emergency colonoscopy without bowel preparation. This is believed to hold substantial promise for the Pure-Vu System to support colonoscopies following limited bowel preparation. This confidence is bolstered by supporting results from other studies.
Changing the Colonoscopy Landscape
The conclusion of this study consolidated that Pure-Vu System as a very useful tool in colonoscopies with patients with IBP, particularly those reported a history of incomplete procedures. 40 procedures have been completed wherein the Pure-Vu System was used as an adjunct to IBP to facilitate the completion of the procedure in 37 patients. Furthermore, the company successfully completed three procedures without the need for bowel preparation in patients with lower GI bleeds.
Scope of MOTS Stock’s Pure-Vu System
The Pure-Vu System was used in 40 patients in the study, with 14 inpatient procedures and 26 outpatient procedures. Each of the patients had IBP, with the system being used to complete the colonoscopy. The indication for colonoscopy was designated as either diagnostic or colorectal cancer (CRC) screening/surveillance. Use of the Pure-Vu System did not interfere with the performance of endoscopic interventions, including biopsy, cold/hot snare polypectomy, or EMR.
Future Outlook for MOTS Stock
MOTS stock is poised to capitalize on the expanded scope of opportunities afforded to it as a result of the promising results of its Pure-Vu System study. The company is keen to maintain the course of its trajectory of success in a bid to usher in unprecedented growth. Current and potential investors are hopeful that management will be able to effectively leverage the resources at their disposal. This is hoped to facilitate significant and sustained increases in shareholder value over the long term.